Physician profile
Robert K Roush
NPI 1508801085
$12,503.00
in general payments reported to CMS, 2019-2025
76 companies · $2,820 in 2025
The $2,820 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,228 · 2020: $709 · 2021: $969 · 2022: $1,894 · 2023: $1,808 · 2024: $2,075 · 2025: $2,820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,619 · Education: $83.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,619.46 |
| Education | $83.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,429.01 | 2019-2025 | Enhertu, Tagrisso, Imfinzi |
| Janssen Biotech, INC. | $762.92 | 2019-2025 | Erleada, Tecvayli, Balversa |
| Pfizer INC. | $705.20 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $624.06 | 2021-2025 | |
| Abbvie INC. | $581.93 | 2019-2025 | Venclexta |
| E.R. Squibb & Sons, L.L.C. | $543.79 | 2019-2025 | Opdualag, Opdivo, Eliquis |
| Merck Sharp & Dohme LLC | $443.93 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Seagen INC. | $414.12 | 2019-2023 | Padcev, Tukysa |
| Genzyme Corporation | $406.31 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $388.86 | 2019-2023 | Imbruvica |
| Karyopharm Therapeutics INC. | $381.34 | 2021-2025 | Xpovio |
| Astellas Pharma US INC | $342.52 | 2020-2025 | Xospata, Xtandi, Padcev |
| Daiichi Sankyo INC. | $334.81 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Genentech USA, INC. | $293.88 | 2019-2025 | Polivy, Phesgo, Perjeta |
| Bayer Healthcare Pharmaceuticals INC. | $255.77 | 2020-2025 |
Show all 76 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $228.19 | 2019-2025 | Trodelvy |
| Lilly USA, LLC | $216.09 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Puma Biotechnology, INC. | $199.99 | 2019-2020 | |
| Genmab U.S., INC. | $190.29 | 2022-2025 | Tivdak, Epkinly |
| Incyte Corporation | $186.69 | 2019-2025 | Monjuvi, Pemazyre, Zynyz |
| Eisai INC. | $179.99 | 2019-2025 | |
| Amgen INC. | $179.07 | 2019-2023 | Vectibix, Nplate, Xgeva |
| Array Biopharma INC | $176.25 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Takeda Pharmaceuticals U.S.A., INC. | $174.14 | 2019-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Sobi, INC | $164.21 | 2022-2025 | |
| Glaxosmithkline, LLC. | $159.42 | 2022-2025 | Jemperli, Zejula, Ojjaara |
| Servier Pharmaceuticals LLC | $159.26 | 2021 | |
| Galvanize Therapeutics, INC | $152.02 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $142.54 | 2019-2025 | Libtayo |
| Celgene Corporation | $133.86 | 2019-2024 | Pomalyst, Reblozyl |
| Shield Therapeutics INC | $131.70 | 2024-2025 | |
| Exelixis INC. | $126.00 | 2019-2025 | Cabometyx |
| Caris Mpi, INC. | $122.58 | 2025 | Mi Cancer Seek |
| Jazz Pharmaceuticals INC. | $106.36 | 2019-2021 | |
| Mirati Therapeutics, INC. | $80.75 | 2023-2024 | Krazati |
| Beone Medicines USA, INC. | $75.43 | 2025 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $75.20 | 2019 | |
| Janssen Pharmaceuticals, INC | $73.99 | 2019-2024 | Xarelto |
| G1 Therapeutics, INC. | $70.55 | 2022-2023 | Cosela |
| Pharmacosmos Therapeutics INC. | $67.36 | 2023-2025 | Monoferric |
| Beigene USA, INC. | $58.78 | 2023-2025 | Brukinsa |
| Tesaro, INC. | $57.65 | 2019 | |
| Kyowa Kirin, INC. | $53.94 | 2019-2020 | |
| Advanced Accelerator Applications | $50.78 | 2019-2020 | |
| Aveo Pharmaceuticals, INC. | $43.54 | 2022-2025 | |
| Rigel Pharmaceuticals, INC. | $40.41 | 2019-2025 | Tavalisse, Rezlidhia, Gavreto |
| Taiho Oncology, INC. | $38.82 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.42 | 2024-2025 | |
| Deciphera Pharmaceuticals INC. | $36.13 | 2023-2025 | Qinlock, Romvimza |
| Verastem, INC. | $35.78 | 2019 | |
| Kite Pharma, INC. | $35.06 | 2019-2023 | Yescarta |
| Shionogi INC | $34.44 | 2019 | |
| Emd Serono, INC. | $32.09 | 2019 | |
| Secura Bio, INC. | $27.58 | 2020-2021 | |
| Octapharma USA, INC. | $26.17 | 2023 | Panzyga |
| Cti Biopharma Corp. | $25.40 | 2023 | Vonjo |
| Fortovia Therapeutics, INC. | $24.83 | 2019 | |
| Alexion Pharmaceuticals, INC. | $23.66 | 2025 | Ultomiris |
| Morphosys, US INC. | $23.47 | 2023 | Monjuvi |
| Tersera Therapeutics LLC | $23.41 | 2021 | |
| Aurobindo Pharma USA, INC. | $23.15 | 2019 | |
| Organon LLC | $22.86 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.73 | 2021 | |
| Blueprint Medicines Corporation | $20.46 | 2022 | |
| Tempus Ai, INC | $20.06 | 2024 | |
| Ferring Pharmaceuticals INC. | $19.88 | 2024 | Adstiladrin |
| Dendreon Pharmaceuticals LLC | $19.54 | 2019 | |
| Epizyme, INC. | $19.41 | 2021 | |
| Fresenius Kabi USA, LLC | $18.03 | 2024 | Stimufend |
| Myriad Genetic Laboratories, INC. | $17.73 | 2024 | Myrisk |
| Teva Pharmaceuticals USA, INC. | $16.96 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $16.94 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $16.41 | 2019 | |
| Clovis Oncology, INC. | $15.80 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.80 | 2020 | |
| Novo Nordisk INC | $11.50 | 2019 |
Drugs and devices associated with these payments
Enhertu $459Imbruvica $415Keytruda $278Lynparza $251Tagrisso $223Padcev $218Imfinzi $207Calquence $202Erleada $188Nubeqa $176Ibrance $175Mektovi $152Braftovi $152Xtandi $148Opdualag $143Xpovio $142Brukinsa $134Scemblix $134Accrufer $132Mi Cancer Seek $123Monjuvi $117Venclexta $117Tivdak $116Stivarga $115Vitrakvi $115Eliquis $109Epkinly $107Kisqali $102Doptelet $99.05Pluvicto $99.04Tecvayli $98.56Xospata $91.44Lorbrena $90.50Fabhalta $87.50Cabometyx $85.89Zejula $84.07Jemperli $84.07Tukysa $82.79Krazati $80.75Sarclisa $69.88Libtayo $67.54Monoferric $67.36Elrexfio $67.21Paxlovid $64.04Talzenna $63.97Xarelto $62.39Comirnaty $62.09Polivy $60.96Xofigo $60.70Trodelvy $60.40Xalkori $57.74Jevtana $57.31Fruzaqla $57.15Vyloy $56.32Pemazyre $48.90Welireg $48.18Balversa $48.17Akeega $47.11Lenvima $46.29Vonjo $45.27Adcetris $44.94Bosulif $44.94Inlyta $44.41Datroway $44.00Jaypirca $40.75Verzenio $40.75Rybrevant $38.97Ojjaara $37.64Cosela $36.67Qinlock $36.13Darzalex $35.56Opdivo $33.26Keytruda Qlex $32.95Ninlaro $29.31Lutathera $27.55Injectafer $26.92Panzyga $26.17Zynyz $25.86Phesgo $25.80Perjeta $25.80Pomalyst $25.65Retevmo $24.97Fotivda $24.55Ultomiris $23.66Reblozyl $22.66Camzyos $22.43Yescarta $21.73Promacta $21.67Tasigna $21.22Lupron Depot $20.70Piqray $20.52Adstiladrin $19.88Vectibix $19.77Xgeva $19.77Nplate $19.77Alunbrig $19.62Orgovyx $19.56Romvimza $19.45Tavalisse $18.73Rezlidhia $18.73
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Roush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.